TF and cervical cancer: With regards to the latter issue, it is worth noting that tisotumab vedotin, an antibody–drug conjugate combining an anti-TF monoclonal antibody and an inhibitor of cell division, has been approved for the treatment of cervical cancer as a first-in-class medication [66,67].